AU2003248907B2 - Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds - Google Patents

Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds Download PDF

Info

Publication number
AU2003248907B2
AU2003248907B2 AU2003248907A AU2003248907A AU2003248907B2 AU 2003248907 B2 AU2003248907 B2 AU 2003248907B2 AU 2003248907 A AU2003248907 A AU 2003248907A AU 2003248907 A AU2003248907 A AU 2003248907A AU 2003248907 B2 AU2003248907 B2 AU 2003248907B2
Authority
AU
Australia
Prior art keywords
pyrrolo
6alkyl
ethoxy
effective amount
7trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003248907A
Other languages
English (en)
Other versions
AU2003248907A1 (en
Inventor
Naomi Burke Anker
Jeannie M. Arruda
Brian Thomas Campbell
Tao Hu
Benito Munoz
Petpiboon Prasit
Brian A. Stearns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2003248907A1 publication Critical patent/AU2003248907A1/en
Application granted granted Critical
Publication of AU2003248907B2 publication Critical patent/AU2003248907B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2003248907A 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds Ceased AU2003248907B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39473402P 2002-07-11 2002-07-11
US60/394,734 2002-07-11
PCT/US2003/021493 WO2004006836A2 (en) 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds

Publications (2)

Publication Number Publication Date
AU2003248907A1 AU2003248907A1 (en) 2004-02-02
AU2003248907B2 true AU2003248907B2 (en) 2007-04-26

Family

ID=30115760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248907A Ceased AU2003248907B2 (en) 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds

Country Status (6)

Country Link
US (1) US7465730B2 (https=)
EP (1) EP1539168A2 (https=)
JP (1) JP2005536507A (https=)
AU (1) AU2003248907B2 (https=)
CA (1) CA2492022A1 (https=)
WO (1) WO2004006836A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28538A1 (es) 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
KR20080064956A (ko) 2005-09-27 2008-07-10 미리어드 제네틱스, 인크. 치료학적 화합물로서의 피롤 유도체
CN101003537A (zh) * 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
TW200914457A (en) 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
BRPI0818193B8 (pt) 2007-09-28 2021-05-25 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto
CN101970427A (zh) 2008-02-29 2011-02-09 Vm生物医药公司 治疗疼痛症状及其它失调的方法
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
HUE035366T2 (en) 2011-06-08 2018-05-02 Daiichi Sankyo Co Ltd A method for the preparation of a bicyclic compound by Claisen rearrangement
ES2659162T3 (es) 2011-06-08 2018-03-14 Daiichi Sankyo Company, Limited Procedimiento de producción de compuesto bicíclico a través de una sal de iminio
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
EP2837689B1 (en) 2012-04-10 2017-02-15 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using enzyme
WO2014069626A1 (ja) * 2012-11-01 2014-05-08 協和発酵キリン株式会社 ピリミドジアゼピノン化合物の製造方法
EP2928891B1 (en) 2012-12-04 2019-02-20 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018100041A1 (en) * 2016-11-30 2018-06-07 Laboratorios Del Dr. Esteve, S.A. Meta substituted phenylpyrazolo- and phenylpyrrolo- pyridazine derivatives having multimodal activity against pain
EP3548489A1 (en) * 2016-11-30 2019-10-09 Esteve Pharmaceuticals, S.A. Ortho substituted phenylpyrazolo- and phenylpyrrolo-pyridazine derivatives having multimodal activity against pain
US20200062767A1 (en) * 2017-05-30 2020-02-27 Esteve Pharmaceuticals, S.A. Substituted pyrrolidinyl and piperidinyl pyrazolopyridazine derivatives having multimodal activity against pain
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
GB9726701D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Organic Chemistry (1959), 24, 551-4. *

Also Published As

Publication number Publication date
AU2003248907A1 (en) 2004-02-02
JP2005536507A (ja) 2005-12-02
US20060154929A1 (en) 2006-07-13
CA2492022A1 (en) 2004-01-22
WO2004006836A3 (en) 2004-04-15
WO2004006836A2 (en) 2004-01-22
EP1539168A2 (en) 2005-06-15
US7465730B2 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
AU2003248907B2 (en) Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds
TWI542590B (zh) １，２-雙取代雜環化合物
TWI760390B (zh) 吡唑並雜芳基類衍生物、其製備方法及其在醫藥上的應用
KR100256707B1 (ko) 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
CN104768932B (zh) Pde4的杂芳基抑制剂
KR101196498B1 (ko) 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘유도체
DE60009033T2 (de) Tricyclische inhibitoren von poly(adp-ribose) polymerasen
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR100820543B1 (ko) ＧＳＫ3β억제제로서의 2-아미노-3-(알킬)-피리미돈유도체
DE69426422T2 (de) Pyridazino-chinolin verbindungen
DE60219672T2 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
CN100376580C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
JPH11514668A (ja) ホスホジエステラーゼ（ｐｄｅ）ｉｖ型および腫瘍壊死因子（ｔｎｆ）阻害物質としての置換インダゾール誘導体及びその使用法
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
AU9455298A (en) Indazole bioisostere replacement of catechol in therapeutically active compounds
WO2012046030A2 (en) Phosphodiesterase inhibitors
KR20030064773A (ko) 항염증제
CN111434662B (zh) 卤代烯丙基胺类化合物及其应用
JPS6136282A (ja) 窒素を含む複素環式化合物からなる医薬品とその製造方法
US5847136A (en) Deazapurine derivatives; a new class of CRF1 specific ligands
WO1999062899A1 (en) Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
CN101874022A (zh) 吲唑丙烯酸酰胺化合物
CA2570046A1 (en) Substituted triazole derivatives as oxytocin antagonists
US20070099950A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
CN101460223A (zh) 用作诱导型一氧化氮合成酶抑制剂的喹诺酮类

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired